Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB
Authors:
- N. Matthew EllinwoodN. Matthew Ellinwood
- Bethann N. ValentineBVBethann N. Valentine
- Andrew S. HessAHAndrew S. Hess
- Jackie K. JensJJJackie K. Jens
- Elizabeth M. SnellaESElizabeth M. Snella
- Maryam JamilMJMaryam Jamil
- Shannon J. HostetterSHShannon J. Hostetter
- Nicholas D. JefferyNJNicholas D. Jeffery
- Jodi D. SmithJSJodi D. Smith
- Suzanne T. MillmanSMSuzanne T. Millman
- Rebecca L. ParsonsRPRebecca L. Parsons
- Mark T. ButtMBMark T. Butt
Open Access
- 1 September 2022
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 382 (3) , 277-286
Abstract
Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B; OMIM #252920) is a lethal, pediatric, neuropathic, autosomal recessive, and lysosomal storage disease with no approved therapy. Patients are deficient in the activity of N-acetyl-alpha-glucosaminidase (NAGLU; EC 3.2.150), necessary for normal lysosomal degradation of the glycosaminoglycan heparan sulfate (HS). Tralesinidase alfa (TA), a fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2, is in development as an enzyme replacement therapy that is administered via intracerebroventricular (ICV) infusion, thus circumventing the blood brain barrier. Previous studies have confirmed ICV infusion results in widespread distribution of TA throughout the brains of mice and nonhuman primates. We assessed the long-term tolerability, pharmacology, and clinical efficacy of TA in a canine model of MPS IIIB over a 20-month study. Long-term administration of TA was well tolerated as compared with administration of vehicle. TA was widely distributed across brain regions, which was confirmed in a follow-up 8-week pharmacokinetic/pharmacodynamic study. MPS IIIB dogs treated for up to 20 months had near-normal levels of HS and nonreducing ends of HS in cerebrospinal fluid and central nervous system (CNS) tissues. TA-treated MPS IIIB dogs performed better on cognitive tests and had improved CNS pathology and decreased cerebellar volume loss relative to vehicle-treated MPS IIIB dogs. These findings demonstrate the ability of TA to prevent or limit the biochemical, pathologic, and cognitive manifestations of canine MPS IIIB disease, thus providing support of its potential long-term tolerability and efficacy in MPS IIIB subjects. SIGNIFICANCE STATEMENT This work illustrates the efficacy and tolerability of tralesinidase alfa as a potential therapeutic for patients with mucopolysaccharidosis type IIIB (MPS IIIB) by documenting that administration to the central nervous system of MPS IIIB dogs prevents the accumulation of disease-associated glycosaminoglycans in lysosomes, hepatomegaly, cerebellar atrophy, and cognitive decline.Keywords
This publication has 38 references indexed in Scilit:
- Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIBPLOS ONE, 2012
- Disease-specific non–reducing end carbohydrate biomarkers for mucopolysaccharidosesNature Chemical Biology, 2012
- A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosisGenes, Brain and Behavior, 2011
- Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)Orphanet Journal of Rare Diseases, 2011
- Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler SyndromesMolecular Therapy, 2011
- Replacing the Enzyme α- l -Iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type IScience Translational Medicine, 2010
- Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidosesProceedings of the National Academy of Sciences, 2009
- Expression and Characterization of Human Recombinant and α-N-ActylglucosaminidaseProtein Expression and Purification, 2001
- Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithmIEEE Transactions on Medical Imaging, 2001
- DEVELOPMENTAL AND DEGENERATIVE PATTERNS ASSOCIATED WITH COGNITIVE, BEHAVIOURAL AND MOTOR DIFFICULTIES IN THE SANFILIPPO SYNDROME: AN EPIDEMIOLOGICAL STUDYJournal of Intellectual Disability Research, 1983